



## Formulary Review & Changes Effective October 1, 2009

The LDI National Pharmacy & Therapeutics committee reviews drugs and drug classes quarterly. Upon review by the committee, a decision is made to ADD, NOT ADD, MAINTAIN or REMOVE the drugs to/from the LDI Preferred Drug formulary. The following is a list of drugs reviewed this quarter by the LDI National Pharmacy & Therapeutics committee and the formulary action that was taken.

Products Reviewed	Formulary Action	Formulary Status F= Formulary, NF = Non-formulary
<i>Central Nervous System Agents</i>		
<b>TNF Inhibitors for Rheumatoid Arthritis</b>		
Enbrel (etanercept)	MAINTAINED	F
Humira (adalimumab)	MAINTAINED	F
Remicade (infliximab)	MAINTAINED	F
Cimzia (certolizumab)	NOT ADDED	NF
Simponi (golimumab)	NOT ADDED	NF
<b>Miscellaneous Stimulants</b>		
Provigil (modafinil)	NOT ADDED	NF
Nuvigil (amodafinil)	NOT ADDED	NF
<i>Miscellaneous Agents</i>		
<b>Erythropoiesis Stimulating Agents (ESAs)</b>		
Procrit (epoetin alfa)	MAINTAINED	F
Epogen (epoetin alfa)	MAINTAINED	F
Aranesp (darbepoetin alfa)	MAINTAINED	F
<i>Urinary Agents</i>		
<b>Overactive Bladder Products</b>		
Detrol (tolterodine)	MAINTAINED	F
Detrol LA (tolterodine)	MAINTAINED	F
Enablex (darifenacin)	NOT ADDED	NF
Gelnique (oxybutynin)	NOT ADDED	NF
Oxytrol (oxybutynin)	NOT ADDED	NF
Sanctura (trospium)	NOT ADDED	NF
Sanctura XR (trospium)	NOT ADDED	NF
Toviaz (fesoterodine)	ADDED	F
Vesicare (solfenacin)	MAINTAINED	F
<i>Cardiovascular</i>		
<b>Cholesterol- Miscellaneous</b>		
Tricor (fenofibrate)	Removed	NF